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Thyroid and Renal Function in Cats Post Low-dose (111Mbq) Radioiodine Therapy 1 
 2 
Objectives: To describe the effect of low-dose (111MBq) radioiodine therapy (RAI) on thyroid and 3 
renal function in hyperthyroid cats over a 12 month follow-up period. 4 
Methods: Client-owned hyperthyroid cats underwent treatment with low-dose RAI and were followed 5 
for 12 months post-RAI treatment. Immediately prior to RAI treatment, and subsequently at one, six 6 
and 12 months post-RAI treatment, thyroid function was evaluated using total thyroxine (TT4) and 7 
thyroid stimulating hormone (TSH) and renal function was evaluated using serum creatinine 8 
concentration and glomerular filtration rate (GFR). 9 
Results: Fifteen of the 24 (63%) cats achieved euthyroidism following low-dose RAI treatment. The 10 
incidence of development of overt hypothyroidism was 25% (6/24 cats). Of the cats developing overt 11 
hypothyroidism, 3/6 (50%) had decreased renal function, with decreased GFR preceding development 12 
of azotaemia in 2 out of 3 of these cats. Transient overt or subclinical hypothyroidism prior to 13 
restoration of euthyroidism was not observed in any cats. 14 
Clinical Significance: Low-dose RAI is effective for most cats with hyperthyroidism, however, overt 15 
hypothyroidism may develop in some. Concurrent early decline in renal function may only be detected 16 
by measuring GFR rather than serum creatinine in some patients.  Monitoring of patients post-RAI 17 
treatment should include TT4 and TSH with consideration of GFR measurement in non-azotaemic cats.  18 
 19 
Introduction 20 
Hyperthyroidism is the most commonly diagnosed endocrinopathy in cats with a reported prevalence of 21 
8.7% in cats over 10 years old (Stephens and others 2014). Radioactive iodine (RAI) treatment is 22 
widely considered the gold standard treatment of hyperthyroidism. The aims of RAI treatment are two-23 
fold; firstly to cure hyperthyroidism and secondly, to prevent the development of iatrogenic 24 
hypothyroidism by administering the minimum effective RAI dose. 25 
Between 15-51% of hyperthyroid cats develop azotaemia following restoration of euthyroidism 26 
(Williams and others 2010, Reinsche and others 2008). Thyroid activity directly impacts renal function; 27 
the hyperthyroid state increases glomerular filtration rate (GFR) and may consequently mask any prior 28 
loss of renal filtration function, restoration of euthyroidism reduces GFR (Boag and others, 2007) and 29 
hypothyroidism decreases GFR further (Panciera and Lefebvre, 2009). 30 
Excessive thyroid suppression can lead to the development of subclinical hypothyroidism (increased 31 
thyroid stimulating hormone [TSH] concentrations with total thyroxine [TT4] concentrations within the 32 
normal reference interval) and overt hypothyroidism (increased TSH concentration and low TT4 33 
concentrations) whilst clinical signs of hypothyroidism may not be apparent (Peterson and Becker, 34 
1995).   35 
Serum or plasma creatinine is routinely used as a marker of renal function, however, it is affected by 36 
non-renal factors, principally muscle mass.  The catabolic effects of hyperthyroidism cause muscle 37 
atrophy and therefore creatinine may be an unreliable indicator of renal function in hyperthyroid cats.  38 
Additionally, endogenous creatinine production is reduced in hypothyroid dogs (Panciera and 39 
Lefebvre, 2009).   40 
The greatest reduction in TT4 concentration is expected in the first month following RAI treatment 41 
(Boag and others 2007, van Hoek and others 2008).  Opposing activities may occur post-RAI treatment 42 
to cause on-going changes in TT4 and TSH concentrations. These include atrophy of thyrocytes due to 43 
sublethal RAI damage resulting in a gradual decrease in TT4 concentrations (Mooney, 1994) and 44 
recovery of function of residual thyroid tissue resulting in an increase in TT4 concentrations. 45 
Continued change in TT4 and TSH concentrations may occur over months to years, however this has 46 
not been well documented in conjunction with renal function beyond six months in cats.  47 
The aim of this study was to describe the effect of low-dose (111MBq) RAI therapy on thyroid and 48 
renal function in hyperthyroid cats over a 12-month follow-up period.  49 
Materials and methods 50 
Study population 51 
Client-owned hyperthyroid cats presenting to a University referral hospital for RAI therapy were 52 
recruited prospectively into the study. The study was of observational cohort design with longitudinal 53 
follow-up. Only cats that received a low dose of 111MBq RAI were included in the study. Cats were 54 
excluded from the study if they required a different dose of RAI therapy (e.g. high dose carcinoma 55 
treatment), were not amenable to handling for repeated blood sampling, had received anti-thyroid 56 
medications within two weeks of presentation, had documented azotaemia prior to RAI therapy or were 57 
fed a restricted iodine diet. Informed consent was obtained from the owners and the study was 58 
conducted with approval from the University Animal Welfare and Ethics Review Board (UIN 59 
UB/12/025). 60 
 61 
Longitudinal study design 62 
At recruitment into the study all cats were hyperthyroid. Cats were re-evaluated at one, six and 12 63 
months post-RAI therapy. At recruitment into the study and at each subsequent time point the 64 
following were performed; full clinical examination, pertinent history, systolic blood pressure 65 
measurement by Doppler technique, blood sampling by jugular venepuncture for biochemistry and 66 
haematology and urine sampling via either cystocentesis or free catch collection. 67 
 68 
Measurement of thyroid function markers 69 
Serum TT4 was measured at a commercial reference laboratory using the Immulite 1000 70 
chemiluminescent immunoassay.i. Serum TSH was measured at a commercial reference laboratoryii 71 
using a previously validated canine assay (Wakeling and others 2008). Thyroid function was 72 
categorised at the one, six and 12 month follow-up visits according to the following criteria: overt 73 
hypothyroid TT4 <15 nmol/l, TSH >0.15 ng/ml (Wakeling and others 2011); subclinical hypothyroid 74 
TT4 >15 – 60 nmol/l, TSH >0.15 ng/ml (Wakeling and others 2011); euthyroid TT4 <60 nmol/l, TSH 75 
< 0.15 ng/ml; hyperthyroid TT4 > 60 nmol/l, TSH <0.03 ng/ml. 76 
 77 
Measurement of renal function markers 78 
Glomerular filtration rate was determined using a previously described slope-intercept iohexol 79 
clearance method (Finch and others 2011). Briefly, a bolus dose of iohexol (OmnipaqueTM [647mg/ml; 80 
300mg of iodine/ml]) was administered intravenously (0.5ml/kg). Blood samples were collected at 120, 81 
180 and 240 minutes post-injection. Iohexol concentrations were determined at an external commercial 82 
laboratory using a high performance capillary electrophoresis HPCE methodiii. Clearance was 83 
determined as dose/AUC, where AUC is area under the plasma concentration versus time curve 84 
determined using a one-compartment model. A previously validated cat specific correction formula for 85 
slope-intercept clearance was applied to correct for the one compartment assumption (Finch and others 86 
2011). In addition, serum creatinine concentrations were determined from a sample collected at the 87 
same time as GFR measurement and measured at a commercial reference laboratoryi. Decreased renal 88 
function was defined as decreased GFR (<0.92 ml/min/kg; Finch, 2014) and/or azotaemia (serum 89 
creatinine >175 µmol/l, the upper limit of laboratory reference interval for feline serum creatinine). 90 
 91 
Data analysis 92 
Descriptive statistics only were performed due to the small numbers of cats included in the study and 93 
the high variability between cats that would limit the statistical power if performing inferential 94 
statistics. Change in renal function over time was calculated by subtracting the measurement (serum 95 
creatinine or GFR) at one time point from the previous time point (e.g baseline – one month). The 96 
within-individual coefficient of variation (CV) % was determined from measurements in individual 97 
cats at all four time points and calculated as (SD/mean) x 100. 98 
 99 
Results 100 
A total of 27 cats were recruited to the study. Twenty-five cats completed the one and six-month 101 
follow-up visit and 21 cats completed the 12-month follow-up visit. The median (range) age at 102 
recruitment to the study was 11 (7 – 16) years. Of the 27 cats, 15 were female neutered, 11 were male 103 
neutered and one was female entire. Twenty-six cats were domestic shorthair and one was domestic 104 
longhair. One cat was excluded from longitudinal data analysis due to uncertain thyroid status. It was 105 
thought this cat may have had euthyroid sick syndrome post-RAI therapy but a final diagnosis was not 106 
available at euthanasia. Median (range) thyroid and renal function markers are presented in Table 1.  107 
At recruitment to the study all cats were hyperthyroid with normal renal function (Table 2). Fifteen 108 
(63%) cats achieved euthyroidism over the 12-month follow-up period. Two cats (8%) were 109 
persistently hyperthyroid and required second RAI treatments. Five cats (21%) classified as 110 
hyperthyroid at one-month post-RAI therapy were euthyroid by six months. Six cats (25%) developed 111 
overt hypothyroidism (two at one month, two at six months, two at 12 months) and of these cats, none 112 
regained thyroid function by the study end point or last follow-up visit. In two cats, development of 113 
overt hypothyroidism was preceded by subclinical hypothyroidism. No cats developed transient overt 114 
or transient subclinical hypothyroidism before euthyroidism, however, one cat had subclinical 115 
hypothyroidism at 12 months and it is unknown whether this resolved. A summary of the longitudinal 116 
data is presented in Figure 1. A total of seven cats (29%) developed decreased renal function. Of the 117 
cats that developed overt hypothyroidism (n = 6), three (50%) developed decreased renal function and 118 
one had borderline renal function (GFR 0.99 ml/min/kg, serum creatinine concentration 175 µmol/l). 119 
Decreased GFR preceded development of azotaemia in 2/3 (67%) cats. The cat with subclinical 120 
hypothyroidism at 12 months (n = 1) had decreased GFR and azotaemia at the six and 12-month revisit.  121 
Of the cats that became euthyroid (n = 15), three (20%) had decreased GFR and normal creatinine at 12 122 
months. Of these three cats, one had decreased GFR and normal creatinine at one, six and 12 months. 123 
There was no decreased renal function in the cats that remained persistently hyperthyroid (n = 2). Mean 124 
± SD change coefficient of variation (CV) in renal function in the hyperthyroid, euthyroid and overtly 125 





The present study of cats receiving low-dose (111MBq) RAI that were followed for a maximum of 12 131 
months post-RAI therapy identified development of overt hypothyroidism in 6/24 (25%), transient 132 
overt or transient subclinical hypothyroidism before euthyroidism in 0% and persistent 133 
hyperthyroidism in 2/24 (8%). All of the cats with subclinical hypothyroidism progressed to overt 134 
hypothyroidism however, one cat (4%) developed subclinical hypothyroidism at the 12-month time 135 
point and it is unknown whether this progressed to overt hypothyroidism or resolved. Of the six cats 136 
that developed overt hypothyroidism, three (50%) developed decreased renal function, with decreased 137 
GFR preceding azotaemia in 2/3 (67%) cats.  138 
 139 
Variable RAI dosing enables individual dosing tailored to the patient, although this is not used in all 140 
clinics treating cats with RAI; this study evaluated a standard fixed ‘low’ dose of 111MBq that was 141 
used to treat cats at the clinic (however, since completion of the study, the protocol at the clinic has 142 
changed to employ variable dosing). Published scoring schedules use the severity of hyperthyroid 143 
clinical signs, TT4 concentrations and goiter size to guide doses, with low doses previously classed as 144 
74-130MBq and 80-120MBq (Mooney, 1994; Peterson and Becker, 1995). In addition, some clinics 145 
use scintigraphy for thyroid gland volume estimation to guide doses, however the optimal method is 146 
undecided (Morre and others 2018).  147 
 148 
A recent study comparing low (defined as 74 MBq) and standard dose (defined as 148 MBq) RAI 149 
treatment for hyperthyroidism in cats reported the incidence of overt hypothyroidism to be 18% with 150 
standard dose RAI and 1% with low dose RAI. It is important to note that a higher cut off for TSH to 151 
define overt hypothyroidism was used compared to the present study (0.3 ng/ml versus 0.15 ng/ml) 152 
(Lucy and others 2017). In the same study, the incidence of subclinical hypothyroidism was 46% in 153 
cats treated with standard dose RAI and 21% in cats treated with low dose RAI. In the present study, 154 
the incidence of development of overt hypothyroidism was higher (25%) and subclinical 155 
hypothyroidism lower (4%). In two out of six (33%) of the cats that developed overt hypothyroidism in 156 
the present study, it was preceded by subclinical hypothyroidism. Therefore, although the earlier study 157 
(Lucy and others 2017) reported a much higher incidence of subclinical hypothyroidism, the study 158 
period was only six months and it is possible that had the cats been followed longer, they could have 159 
progressed to overt hypothyroidism. Conversely, 4/6 overtly hypothyroid cats in the present study 160 
could be classed as mildly hyperthyroid at baseline (Petersen and Becker 1995), and these cats were 161 
potentially excessively treated with 111MBq. Indeed, 111MBq may not be considered ‘low-dose’ when 162 
compared to low doses used in other studies. The incidence of development of overt hypothyroidism 163 
(25%) in the present study is in line with that of cats receiving medical management alone or in 164 
combination with thyroidectomy (See Table 4). The incidence of development of subclinical 165 
hypothyroidism (4%) is in line with the study by Williams and others (Williams and others 2010a) but 166 
lower than the studies by Aldridge and others (Aldridge and others 2015) and Lucy and others (Lucy 167 
and others 2017) (See Table 4). Differences in the incidence of subclinical and overt hypothyroidism 168 
may partly be explained by the use of different assays to measure TSH in the studies and also the upper 169 
reference limit of TSH and lower limit for TT4 used to define a cat as being hypothyroid (subclinical or 170 
overt). Standardisation of both measurement of TSH and the definition of subclinical and overt 171 
hypothyroidism would be helpful for on-going research into this important and evolving area of feline 172 
hyperthyroid management. 173 
 174 
 175 
In the present study, 4/6 (67%) of cats that developed overt hypothyroidism did so within the first six 176 
months post-RAI therapy. Spontaneous recovery of thyroid function was not observed in any of the 177 
overtly hypothyroid cats. In human patients developing hypothyroidism post-RAI, 86% do so in the 178 
first 6 months and the rate is low after 12 months (3%/year) (Peacey and others 2012). Changes in 179 
thyroid function in cats may occur longer than 12 months post-RAI therapy. Normalization of TSH and 180 
TT4 has been reported over 3-21 months (median 6 months) and development of hypothyroidism after 181 
18 months (Peterson and Rishniw, 2017). The rate of development of overt or subclinical 182 
hypothyroidism and also recovery of thyroid function beyond 12 months in cats warrants further 183 
studies. 184 
 185 
Previous studies have reported the incidence of development of azotaemia within six months of 186 
initiating medical management, RAI therapy or thyroidectomy for hyperthyroidism to be between 15% 187 
and 51% (Becker and others 2000, Boag and others 2007, Graves and others 1994, Lucy and others 188 
2017, Williams and others 2010a, Williams and others 2010b, Reinsche et al, 2008). In a previous 189 
study of cats treated with standard dose RAI (148MBq) the incidence of azotaemia was 46% versus 190 
29% in cats treated with low dose RAI (74MBq) (Lucy and others 2017). In cats with normal renal and 191 
thyroid function at baseline, the incidence of development of azotaemia over 12 months is reported to 192 
be between 11% (Finch and others 2016) and 30.5% (Jepson and others 2009). The present study found 193 
the incidence of reduced renal function over 12 months to be 29%. Cats with iatrogenic 194 
hypothyroidism are at increased risk of developing azotaemia compared to cats that remain euthyroid 195 
(Williams and others 2010a). Of the overtly hypothyroid cats in the present study, 50% had reduced 196 
renal function compared to 20% of euthyroid cats. In the overtly hypothyroid cats, decreased GFR 197 
preceded development of azotaemia in 2/3 of the cats. However, as one of the hypothyroid cats had 198 
both decreased GFR and azotaemia at the one-month time point when first identified to be overtly 199 
hypothyroid, it is unknown whether a decline in GFR preceded azotaemia in this cat and therefore, it is 200 
possible up to 100% of the overtly hypothyroid cats had a decline in GFR prior to development of 201 
azotaemia. Of all of the cats in the study with reduced renal function, 71% remained non-azotaemic 202 
despite having reduced GFR. These findings are unsurprising given the lack of sensitivity of creatinine 203 
at detecting early decline in renal function (Finch 2014). However, in cats with hypothyroidism, 204 
decreased endogenous creatinine production may also influence circulating creatinine concentrations. 205 
This has been shown in dogs with experimentally induced hypothyroidism (Panciera and Lefebvre 206 
2009). The present study highlights the importance of measuring GFR rather than serum creatinine 207 
concentration to accurately assess renal function in non-azotaemic cats with the potential to be 208 
hypothyroid. Further studies are required exploring other markers of GFR such as SDMA.  209 
The largest change in renal function was seen in the first month following RAI (see Table 3) and this is 210 
in line with findings reported in previous studies (Boag and others 2007, van Hoek and others 2008). 211 
The greatest within-individual variation in renal function over time occurred in the overtly hypothyroid 212 
cats (see Table 3). This likely reflects that this was the group with the largest number of cats with a 213 
decrease in renal function. A recent study reported the mean within-individual CV for GFR and serum 214 
creatinine concentration to be 28.94 and 8.82% respectively in non-azotaemic cats and 19.98 and 215 
6.81% in azotaemic cats (Finch and others 2018). It is interesting that the within-individual variation 216 
for serum creatinine concentration was lower in the previous study compared to the present study. This 217 
may reflect differences in the reference laboratories used to measure serum creatinine concentration or 218 
may suggest there is greater variability in serum creatinine concentration in previously hyperthyroid 219 
cats treated with RAI compared to euthyroid cats. Greater variability in serum creatinine is not 220 
unexpected in cats that were previously hyperthyroid as change in muscle mass in such cats will be 221 
associated with change in endogenous creatinine production 222 
Correction of iatrogenic hypothyroidism resolved azotaemia in 50% of cats (Williams and others 223 
2014). However, given that 2/3 (67%) of hypothyroid cats with decreased GFR were non-azotaemic in 224 
the present study, it is possible that many cats with resolved azotaemia may still have reduced renal 225 
function that is not detected by measuring serum creatinine concentration alone. Indeed, changes in 226 
creatinine concentrations may simply be related to changes in endogenous creatinine production. 227 
Hyperthyroid cats have been reported not to regain normal muscle mass following treatment for 228 
hyperthyroidism, thus impacting on endogenous creatinine concentration (Peterson and others 2016). 229 
Therefore, measurement of GFR may prove to be important in not only defining renal function and 230 
guiding management of cats with iatrogenic hypothyroidism but also in monitoring renal function once 231 
management has been initiated. Development of kidney disease is a predictor of negative outcome 232 
following RAI therapy in cats (Slater and others 2001) and cats with iatrogenic hypothyroidism that 233 
develop azotaemia have reduced survival compared to non-azotaemic cats without iatrogenic 234 
hypothyroidism (Williams and others 2010a). 'Therefore, identifying a decline in renal function early in 235 
cats with iatrogenic hypothyroidism and initiating appropriate management such as L-thyroxine is also 236 
likely to be important in improving prognosis. 237 
 238 
In the present study, two cats (8%) remained persistently hyperthyroid despite partial responses 239 
necessitating second RAI treatments. This is comparable to a six-month prevalence of hyperthyroidism 240 
of 7% reported by Morre and others in a group of cats also treated with 111MBq RAI (Morre and 241 
others 2018). Of the two cats that remained persistently hyperthyroid in the present study, one had a 242 
very high TT4 concentration pre-RAI (351 nmol/l) whilst the other hyperthyroid cat along with the 243 
remainder of the cats in the study had TT4 <250 nmol/l. Based on this and unpublished data from cats 244 
undergoing RAI therapy at the University referral hospital, the authors recommend that low dose RAI 245 
(111MBq) be reserved for cats with mild to moderate hyperthyroidism (i.e. TT4 <250nmol/l). 246 
 247 
The present study has a number of limitations. Firstly, the small numbers of cats included in the study. 248 
Secondly, the follow-up period of only 12 months. However, this is the first study to provide data from 249 
cats receiving RAI therapy for longer than six months follow-up using TSH in conjunction with TT4 250 
concentrations to define thyroid status and GFR to assess renal function. Finally, the use of iohexol 251 
clearance for GFR measurement prior to RAI therapy. Iodine containing contrast agents may interfere 252 
with thyroid uptake of RAI. However, it has been shown that although cats pretreated with iohexol as 253 
part of GFR measurement have decreased uptake of RAI, the effective half-life of RAI and therapy 254 
outcome do not differ from cats not pretreated with iohexol (Peremans and others 2008).  255 
 256 
To conclude, low dose (111MBq) RAI was associated with an incidence of development of overt 257 
hypothyroidism of 25%. Thyroid function including TT4 and TSH should be monitored longer-term in 258 
all cats that have undergone RAI as hypothyroidism can develop at variable rates in the first year post 259 
treatment. In addition, renal function should ideally be monitored by GFR in non-azotaemic cats to 260 
ensure early and accurate detection of any decline, particularly in cats with the potential to develop 261 
hypothyroidism.  262 
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